Daidzein protects caco-2 cells against lipopolysaccharide-induced intestinal epithelial barrier injury by suppressing pi3k/akt and p38 pathways

HIGHLIGHTS

• who: Baoping Zhang and collaborators from the School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China have published the research work: Daidzein Protects Caco-2 Cells against Lipopolysaccharide-Induced Intestinal Epithelial Barrier Injury by Suppressing PI3K/AKT and P38 Pathways, in the Journal: Molecules 2022, 8928 of 12/Dec/2022
• what: The study showed that could resist LPS-induced intestinal epithelial barrier injury and the mechanism is related to the PI3K/AKT and Therefore could be a candidate as a dietary supplementation or drug to prevent or cure diarrhea. The authors used a LPS . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.